Addex Therapeutics Ltd (NASDAQ:ADXN – Get Free Report) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 97,500 shares, an increase of 9,650.0% from the August 15th total of 1,000 shares. Currently, 11.9% of the company’s stock are short sold. Based on an average daily volume of 272,700 shares, the short-interest ratio is currently 0.4 days.
Addex Therapeutics Stock Down 0.9 %
Shares of Addex Therapeutics stock opened at $10.21 on Friday. The company has a 50 day moving average price of $8.73 and a 200 day moving average price of $10.64. The firm has a market capitalization of $10.82 million, a P/E ratio of -0.59 and a beta of 1.79. Addex Therapeutics has a 52 week low of $5.00 and a 52 week high of $27.90.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Addex Therapeutics in a research note on Wednesday, August 28th.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Read More
- Five stocks we like better than Addex Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- 3 Leveraged ETFs to Multiply Returns
- Roth IRA Calculator: Calculate Your Potential Returns
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- How to Most Effectively Use the MarketBeat Earnings Screener
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.